RHO and cancer: The regulatory mechanism of these inhibitors are completely different from previous Rho inhibitors (Figure 4i).[14] Moreover, the derivative compound DC‐Rhoin04 is capable of inhibiting activation of cellular Rho GTPases as low as single‐digit micromoles, leading to attenuated invasive behavior of cancer cells.